In Silico Identification of Selective KRAS G12D Inhibitor via Machine Learning‐Based Molecular Docking Combined with Molecular Dynamics Simulation
- 25 July 2024
- journal article
- research article
- Published by Wiley in Advanced Theory and Simulations
- Vol. 7 (10)
Abstract
KRAS G12D mutation is prevalent in various cancers and is associated with poor prognosis. This study aimed to identify potential drug candidates targeting KRAS G12D using combined machine learning, virtual screening, molecular docking, and molecular dynamics (MD) simulations. The training and test sets are constructed based on a selection of inhibitors targeting the KRAS G12D mutant from the ChEMBL library. A random forest machine learning algorithm is developed to predict potential KRAS G12D binders. Molecular docking and the MM/PBSA binding energy are used to identify the lead compounds. The compound NPC489264 is identified as the top candidate, exhibiting favorable docking energy for the KRAS G12D mutant (−13.16 kcal mol−1). A hydrogen bond between the mutated Asp12 residue in the KRAS G12D mutant and NPC489264 is found to be a key interaction between these 2 molecules. MD simulations and MM/PBSA analysis revealed the strong binding affinity of NPC489264 to the G12D mutant (−5.49 kcal mol−1) compared to the wild type (10.17 kcal mol−1). These findings suggest that NPC489264 is a promising lead compound for further development of KRAS G12D‐targeted cancer therapies.Keywords
Funding Information
- National Research Council of Thailand (N42A650193)
This publication has 41 references indexed in Scilit:
- Beyond structural bioinformatics for genomics with dynamics characterization of an expanded KRAS mutational landscapeComputational and Structural Biotechnology Journal, 2023
- Machine learning models to select potential inhibitors of acetylcholinesterase activity from SistematX: a natural products databaseMolecular Diversity, 2021
- Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflowMolecular Diversity, 2021
- How Good Is Machine Learning in Predicting All-Cause 30-Day Hospital Readmission? Evidence From Administrative DataValue in Health, 2020
- Molecular epidemiology and diagnostics of KRAS mutations in human cancerCancer and Metastasis Reviews, 2020
- Structure-based inhibitor design of mutant RAS proteins—a paradigm shiftCancer and Metastasis Reviews, 2020
- RAS Proteins and Their Regulators in Human DiseaseCell, 2017
- Multivalent Small-Molecule Pan-RAS InhibitorsCell, 2017
- RalGDS family members couple Ras to Ral signalling and that's not allCellular Signalling, 2010
- AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibilityJournal of Computational Chemistry, 2009